Business Wire

Toshiba Launches New ELERA™ Security Suite to Address the Industry’s Challenges Around Shrink

12.9.2023 16:05:00 EEST | Business Wire | Press release

Share

The new ELERA Security Suite from Toshiba Global Commerce Solutions empowers retailers to minimize shrink while providing consumers with enhanced checkout experiences and reduced friction. According to the latest data from the National Retail Federation, retail shrink accounted for $94.5 billion in losses in 2021 in the U.S. and continues to be a critical challenge for retailers. Available later this year, the ELERA™ Security Suite offers retailers a comprehensive solution to protect their bottom line and combat multiple forms of shrink.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230912900113/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The A.I.-powered ELERA™ Security Suite offers retailers a comprehensive solution to minimize shrink while providing consumers with enhanced checkout experiences. (Photo: Business Wire)

“In a world where every second and every cent counts, ELERA™ Security Suite is not just a tool but a strategy—turning data into decisions and losses into profits,” said Yevgeni Tsirulnik, SVP of Innovation and Incubation at Toshiba Global Commerce Solutions. “As global leaders in retail solutions, our Toshiba team and partners came together to envision and develop the A.I.-powered ELERA Security Suite to enhance their loss prevention measures that have a direct and positive impact on retailer profits while also improving the shopper experience.”

The ELERA Security Suite end-to-end solution deployed as-a-service through Toshiba’s IoT platform, fully orchestrates computer vision cameras with advanced edge A.I., to enhance profit protections and shopper experiences through:

  • Monitoring consumer behavior in real-time – without servers or processing lag – via TCx® EDGEcam+ and multiple sensors, which adds enhanced security throughout the checkout area
  • Responding to incidents as they occur for more impactful and timely resolutions with leading A.I.-powered computer vision
  • Notifying shoppers of potential errors through proactive alerts and allowing them to correct the issue themselves – minimizing employee intervention and improving the checkout experience
  • Differentiating customer’s items vs. store items they’re purchasing, improving recognition accuracy, and reducing incorrect warnings

The modular ELERA Security Suite system empowers retailers with versatility and opportunities to leverage the latest technology to meet their business needs. The ELERA Security Suite can be part of the overall ELERA™ solution, or it can be attached to other Toshiba or third-party POS systems.

“We are excited to expand our collaboration with Toshiba Global Commerce Solutions by integrating the Qualcomm® QRB5165 System-on-Chip (SoC) for IoT into Toshiba’s TCx EDGEcam+ to provide one of the best A.I. edge processing platforms in the market,” stated Art Miller, Vice President, Business Development and Head of Retail and Payments, Qualcomm Technologies, Inc. “Qualcomm QRB5165 SoC brings distributed A.I. and compute capabilities to the edge eliminating the need for expensive and power-intensive servers in the back of the store.”

This A.I.-driven solution presents benefits to both retailers and consumers across multiple touchpoints. ELERA™ Security Suite expands on the previously available ELERA™ Produce Recognition that leverages A.I. and computer vision to accurately and efficiently identify produce and eliminate the need to input produce codes at checkout manually. Retailers are already benefiting from the produce recognition innovation through improved inventory accuracy and throughput in the self-service experience enabling a more seamless checkout and positive consumer experience. Based on recent retailer data, Toshiba has found that shoppers save as much as five seconds per produce item lookup during checkout.

Retailers that invest in the ELERA Security Suite can see strong returns on their investment in this new technology suite through increased inventory accuracy, decreased store staff intervention, and increased adoption of their self-checkout lanes. Given Toshiba’s focus on retailers and consumer privacy, we also offer peace of mind by meeting the requirements of applicable data privacy laws, including all federal, state, regional, territorial, national, and local laws, regulations, and rules by any government agency or authority that relate to the processing or the security of personal data.

Toshiba experts will be at GroceryShop 2023 in Las Vegas from September 19-21 to showcase the ELERA Security Suite and a portfolio of other retail solutions that enable retailers to re-imagine, accelerate, and differentiate their shopping experiences (booth #1050).

About Toshiba Global Commerce Solutions

Toshiba Global Commerce Solutions empowers retail to thrive and prosper through a dynamic ecosystem of smarter, more agile solutions and services that enable retailers to resiliently evolve with generations of consumers and adapt to market conditions. Supported by a global organization of devoted employees and partners, retailers gain more visibility and control over operations while enjoying the flexibility to build, scale, and transform retail experiences that anticipate and fulfill consumers’ ever-changing needs. Visit commerce.toshiba.com and engage with us on X, formerly known as Twitter, Facebook, LinkedIn, Instagram, and YouTube, to learn more.

Toshiba Global Commerce Solutions is a wholly owned subsidiary of Toshiba Tec Corporation, which is traded on the Tokyo Stock Exchange.

Qualcomm

Qualcomm is a trademark or registered trademark of Qualcomm incorporated. Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Toshiba Global Commerce Solutions
Elizabeth Romero
Director, Corporate Communications
elizabeth.romero@toshibagcs.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye